Table 3.
Vaccine effectiveness for three doses of BNT162b2 against the Omicron (B.1.1.529) variant.
| Characteristic | All adults |
<50 years |
≥50 years |
≥75 years |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VE (95% CI) | OR (95% CI) | P-value | VE (95% CI) | OR (95% CI) | P-value | VE (95% CI) | OR (95% CI) | P-value | VE (95% CI) | OR (95% CI) | P-value | |
| 1. Hospitalisation | ||||||||||||
| Unadjusted vaccine effectiveness | ||||||||||||
| Three doses | 28.4 (7.1–44.8) | 0.716 (0.552–0.929) | 0.012 | 32.6 (-24–64.2) | 0.674 (0.358–1.240) | 0.2 | 26.5 (0.5–45.7) | 0.735 (0.543–0.995) | 0.046 | 30.7 (−2.8–53.1) | 0.693 (0.469–1.028) | 0.067 |
| Adjusted vaccine effectiveness - Logistic regression model | ||||||||||||
| Three doses | 30.9 (5.9–49.3) | 0.691 (0.507–0.941) | 0.019 | 42.6 (−17.4–72.7) | 0.574 (0.273–1.174) | 0.13 | 32.0 (3.8–52.0) | 0.680 (0.480–0.962) | 0.029 | 47.2 (16.8–66.6) | 0.528 (0.334–0.832) | 0.006 |
| Age | 1.001 (0.990–1.012) | 0.9 | 1.029 (0.991–1.071) | 0.14 | 0.994 (0.977–1.011) | 0.5 | 1.005 (0.971–1.041) | 0.8 | ||||
| Sex (male) | 1.005 (0.756–1.335) | >0.9 | 0.565 (0.288–1.086) | 0.090 | 1.136 (0.824–1.569) | 0.4 | 1.388 (0.927–2.085) | 0.11 | ||||
| CCI | 0.957 (0.877–1.042) | 0.3 | 0.824 (0.544–1.196) | 0.3 | 0.972 (0.887–1.063) | 0.5 | 1.010 (0.904–1.128) | 0.9 | ||||
| IMD | 1.017 (0.967–1.069) | 0.5 | 1.160 (1.035–1.307) | 0.012 | 0.987 (0.932–1.044) | 0.6 | 0.994 (0.926–1.067) | 0.9 | ||||
| Prevalence | 1.001 (1.001-1.002) | <0.001 | 1.001 (1.000–1.002) | 0.019 | 1.001 (1.001-1.002) | <0.001 | 1.001 (1.001-1.002) | <0.001 | ||||
| Week |
0.959 (0.929–0.991) |
0.011 |
0.954 (0.891–1.020) |
0.2 |
0.962 (0.926–0.999) |
0.042 |
0.935 (0.889–0.982) |
0.008 |
||||
| 2. Hospital admission length >3 Days | ||||||||||||
| Unadjusted vaccine effectiveness | ||||||||||||
| Three doses | −9.1 (−74.1–31.5) | 1.091 (0.685–1.741) | 0.7 | 72.8 (−10.4–96) | 0.272 (0.040–1.104) | 0.11 | 21.0 (−39.9–55.9) | 0.790 (0.441–1.399) | 0.4 | 9.6 (−93.1–59.1) | 0.904 (0.409–1.931) | 0.8 |
| Adjusted vaccine effectiveness - Logistic regression model | ||||||||||||
| Three doses | 56.1 (20.6–76.5) | 0.439 (0.235–0.794) | 0.008 | 74.4 (−24.2–96.9) | 0.256 (0.031–1.242) | 0.13 | 49.8 (3.8–74.7) | 0.502 (0.253–0.962) | 0.042 | 19.6 (−76.2–64.8) | 0.804 (0.352–1.762) | 0.6 |
| Age | 1.036 (1.014–1.059) | 0.001 | 1.032 (0.953–1.121) | 0.4 | 1.031 (0.999–1.064) | 0.060 | 1.011 (0.946–1.082) | 0.7 | ||||
| Sex (male) | 1.438 (0.848–2.441) | 0.2 | 2.548 (0.684–9.903) | 0.2 | 1.195 (0.657–2.174) | 0.6 | 1.247 (0.601–2.585) | 0.6 | ||||
| CCI | 1.088 (0.923–1.298) | 0.3 | 1.986 (0.926–5.133) | 0.094 | 1.056 (0.891–1.267) | 0.5 | 0.995 (0.819–1.222) | >0.9 | ||||
| IMD | 1.085 (0.985–1.196) | 0.10 | 0.939 (0.754–1.156) | 0.6 | 1.149 (1.025–1.292) | 0.018 | 1.145 (0.996–1.324) | 0.061 | ||||
| Week |
0.932 (0.888–0.977) |
0.004 |
0.917 (0.810–1.024) |
0.14 |
0.927 (0.876–0.978) |
0.007 |
0.949 (0.887–1.014) |
0.13 |
||||
| 3. WHO score >5 | ||||||||||||
| Unadjusted vaccine effectiveness | ||||||||||||
| Three doses | 23.4 (−18.7–50.6) | 0.766 (0.494–1.187) | 0.2 | 80.7 (−8.8–99.0) | 0.193 (0.010–1.088) | 0.13 | 41.5 (4.0–64.5) | 0.585 (0.355–0.960) | 0.035 | 43.3 (−6.7–70.2) | 0.567 (0.298–1.067) | 0.081 |
| Adjusted vaccine effectiveness - Logistic regression model | ||||||||||||
| Three doses | 58.8 (31.2–75.8) | 0.412 (0.242–0.688) | <0.001 | 81.6 (−21.1–99.1) | 0.184 (0.009–1.211) | 0.14 | 54.4 (21.6–73.9) | 0.456 (0.261–0.784) | 0.005 | 49.2 (0.2–74.7) | 0.508 (0.253–0.998) | 0.052 |
| Age | 1.026 (1.008–1.045) | 0.005 | 0.971 (0.885–1.059) | 0.5 | 1.018 (0.992–1.045) | 0.2 | 1.005 (0.950–1.063) | 0.9 | ||||
| Sex (male) | 0.934 (0.579–1.501) | 0.8 | 2.982 (0.727–13.043) | 0.13 | 0.770 (0.461–1.284) | 0.3 | 0.730 (0.385–1.376) | 0.3 | ||||
| CCI | 1.085 (0.948–1.246) | 0.2 | 1.907 (0.916–4.525) | 0.10 | 1.044 (0.909–1.200) | 0.5 | 0.965 (0.815–1.137) | 0.7 | ||||
| IMD | 1.052 (0.966–1.146) | 0.2 | 1.258 (0.994–1.642) | 0.067 | 1.037 (0.943–1.140) | 0.5 | 1.095 (0.973–1.236) | 0.13 | ||||
| Week |
0.969 (0.937–1.001) |
0.059 |
0.968 (0.874–1.060) |
0.5 |
0.960 (0.925–0.995) |
0.029 |
0.909 (0.858–0.958) |
<0.001 |
||||
| 4. Supplementary oxygen FiO2 >28% | ||||||||||||
| Unadjusted vaccine effectiveness | ||||||||||||
| Three doses | 15.9 (−37.6–48.6) | 0.841 (0.514–1.376) | 0.5 | 63.2 (−127.2–98.1) | 0.368 (0.019–2.272) | 0.4 | 32.3 (−15.7–60.4) | 0.677 (0.396–1.157) | 0.2 | 17.7 (−63.3–57.9) | 0.823 (0.421–1.633) | 0.6 |
| Adjusted vaccine effectiveness - Logistic regression model | ||||||||||||
| Three doses | 41.5 (−0.4–66.3) | 0.585 (0.337–1.004) | 0.053 | 64.6 (−147.5–98.3) | 0.354 (0.017–2.475) | 0.4 | 37.1 (−11.2–64.5) | 0.629 (0.355–1.112) | 0.11 | 15.6 (−74.7–58.6) | 0.844 (0.414–1.747) | 0.6 |
| Age | 1.036 (1.015–1.058) | <0.001 | 1.041 (0.938–1.160) | 0.4 | 1.024 (0.996–1.053) | 0.10 | 0.993 (0.936–1.053) | 0.8 | ||||
| Sex (male) | 0.899 (0.537–1.505) | 0.7 | 2.821 (0.544–15.230) | 0.2 | 0.760 (0.440–1.311) | 0.3 | 0.858 (0.433–1.709) | 0.7 | ||||
| CCI | 0.919 (0.781–1.067) | 0.3 | 1.548 (0.620–3.352) | 0.3 | 0.900 (0.759–1.050) | 0.2 | 0.829 (0.662–1.010) | 0.080 | ||||
| IMD | 0.970 (0.882–1.065) | 0.5 | 1.204 (0.916–1.640) | 0.2 | 0.954 (0.860–1.056) | 0.4 | 1.002 (0.881–1.139) | >0.9 | ||||
| Week | 0.986 (0.950–1.021) | 0.4 | 0.967 (0.851–1.075) | 0.6 | 0.979 (0.940–1.017) | 0.3 | 0.903 (0.846–0.958) | 0.001 | ||||
CI, Confidence Interval; CCI, Charlson comorbidity index; FiO2, Fraction inspired oxygen; IMD, index of multiple deprivation; OR, Odds Ratio; VE, vaccine effectiveness; WHO, World Health Organisation.
The results of Matched Conditional Logistic Regression models are shown in Supplementary Data 3.